Sfoglia per Autore  

Opzioni
Mostrati risultati da 1 a 20 di 346
Titolo Tipologia Data di pubblicazione Autori File
Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients 01 - Articolo su rivista 2024 Zappaterra, AriannaCivettini, IvanPierini, SilviaGambacorti-Passerini, CarloCairoli, Roberto +
Late relapse of chronic myeloid leukemia after allogeneic bone marrow transplantation points to KANSARL (KANSL1::ARL17A) alteration: a case report with insights on the molecular landscape 01 - Articolo su rivista 2024 Fontana, DZambrotta, GPMPiazza, RGambacorti-Passerini, C +
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 01 - Articolo su rivista 2024 Crespiatico I.Mastini C.D'Aliberti D.Mauri M.Mercado C. M.Fontana D.Spinelli S.Crippa V.Inzoli E.Manghisi B.Civettini I.Ramazzotti D.Sangiorgio V.Brambilla V.Aroldi A.Barone C.Orsenigo R.Serafini M.Mottadelli F.Cazzaniga G.Pagni F.Azzoni E.Gambacorti Passerini C.Elli E. M.Mologni L.Piazza R. +
Idiopathic erythrocytosis: a germline disease? 01 - Articolo su rivista 2024 Elli, E. M.Mauri, M.D’Aliberti, D.Crespiatico, I.Fontana, D.Redaelli, S.Pelucchi, S.Spinelli, S.Manghisi, B.Cavalca, F.Aroldi, A.Ripamonti, A.Palamini, S.Mottadelli, F.Massimino, L.Ramazzotti, D.Cazzaniga, G.Piperno, A.Gambacorti-Passerini, C.Piazza, R. +
Efficacy and safety of bosutinib in patients treated with prior imatinib and/or dasatinib and/or nilotinib: Subgroup analyses from the phase 4 BYOND study 01 - Articolo su rivista 2024 Gambacorti-Passerini C. +
Impact of age and comorbidities on the efficacy and tolerability of bosutinib in previously treated patients with chronic myeloid leukemia: results from the phase 4 BYOND study 01 - Articolo su rivista 2024 Gambacorti-Passerini C. +
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma 01 - Articolo su rivista 2023 Mastini C.D’Aliberti D.Mologni L.Piazza R.Gambacorti Passerini C. +
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO study 01 - Articolo su rivista 2023 Piazza R.Guglielmana V.Colombo F.Antolini L.Gambacorti-Passerini C. +
Effects of blocking CD24 and CD47 'don't eat me' signals in combination with rituximab in mantle-cell lymphoma and chronic lymphocytic leukaemia 01 - Articolo su rivista 2023 Aroldi, AMauri, MRamazzotti, DVilla, MMalighetti, FCrippa, VCocito, FBorella, CBossi, ESteidl, CScollo, CMologni, LPiazza, RGambacorti Passerini, C +
Evaluating the performance of large language models in haematopoietic stem cell transplantation decision-making 01 - Articolo su rivista 2023 Civettini, IvanZappaterra, AriannaGranelli, Bianca MariaRindone, GiovanniAroldi, AndreaBonfanti, StefanoColombo, FedericaFedele, MarilenaPerfetti, PaolaTerruzzi, ElisabettaGambacorti-Passerini, CarloRamazzotti, DanieleCavalca, Fabrizio +
DNA Damage Response (DDR) Is Associated With Treatment-free Remission in Chronic Myeloid Leukemia Patients 01 - Articolo su rivista 2023 Malighetti, FedericaMauri, MarioVilla, MatteoManghisi, BeatriceInzoli, ElenaRindone, GiovanniCivettini, IvanGuglielmana, VeronicaRamazzotti, DanieleBombelli, SilviaPerego, RobertoPiazza, RoccoMologni, LucaGambacorti-Passerini, Carlo +
Cross-intolerance with bosutinib after prior tyrosine kinase inhibitors for Philadelphia chromosome-positive leukemia: long-term analysis of a phase I/II study 01 - Articolo su rivista 2023 Gambacorti-Passerini C. +
Author Correction: The landscape of viral associations in human cancers (Nature Genetics, (2020), 52, 3, (320-330), 10.1038/s41588-019-0558-9) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: The evolutionary history of 2,658 cancers (Nature, (2020), 578, 7793, (122-128), 10.1038/s41586-019-1907-7) 99 - Altro 2023 Gambacorti-Passerini C. +
A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas 01 - Articolo su rivista 2023 Rindone, GiovanniAroldi, AndreaBossi, ElisaVerga, LuisaZambrotta, GiovanniTarantino, SaraPiazza, RoccoGambacorti-Passerini, Carlo +
SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort 01 - Articolo su rivista 2023 Cairoli R.Gambacorti-Passerini C. +
Author Correction: Butler enables rapid cloud-based analysis of thousands of human genomes (Nature Biotechnology, (2020), 38, 3, (288-292), 10.1038/s41587-019-0360-3) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer (Nature Genetics, (2020), 52, 3, (294-305), 10.1038/s41588-019-0564-y) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (Nature Genetics, (2020), 52, 3, (342-352), 10.1038/s41588-019-0557-x) 99 - Altro 2023 Gambacorti-Passerini C. +
Author Correction: Comprehensive molecular characterization of mitochondrial genomes in human cancers (Nature Genetics, (2020), 52, 3, (342-352), 10.1038/s41588-019-0557-x) 99 - Altro 2023 Gambacorti-Passerini C. +
Mostrati risultati da 1 a 20 di 346
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile